News

AbbVie and Alector are partnering on developing and commercializing treatments for Alzheimer’s and other neurodegenerative diseases. Alector brings an immuno-neurology discovery platform to the partnership. AbbVie brings its expertise in research, development, and commercialization of therapies targeting Alzheimer’s. It has become increasingly clear that the immune system plays a key…

The Alzheimer’s Association and Alzheimer’s Drug Discovery Foundation will fund a Phase 2 clinical trial of a combination therapy that Amylyx Pharmaceuticals is developing for Alzheimer’s disease. Amylyx will receive $1.85 million for the trial of AMX0035, which consists of an oral formulation of sodium phenylbutyrate (PB) and tauroursodeoxycholic-acid…

Biogen  and Eisai have deepened their partnership by agreeing to work together on the continued development of the Alzheimer’s therapy aducanumab (BIIB037), which targets harmful beta amyloid protein clusters. The U.S. and Japanese companies are already collaborating on the development of elenbecestat (E2609) and BAN2401, which also target beta…

The U.S. Food and Drug Administration has granted Fast Track status to Alzheon’s Alzheimer’s therapy candidate ALZ-801, which studies have shown prevents the clustering of harmful proteins associated with the disease. “We look forward to working closely with the FDA as we seek to make progress in developing a…

The founders of Edelman Financial Services have donated $25 million to a group called the Alzheimer’s Disease Team to help it compete for a global XPRIZE. Jean and Ric Edelman announced the donation at the 2017 XPRIZE Visioneers Summit in Los Angeles on Oct. 19. The Alzheimer’s team, which received the…

M3 Biotechnology will test a regenerative therapy for Alzheimer’s in a Phase 1 clinical trial. The Seattle-based company designed NDX-1017 to slow or stop the progression of the disease, and perhaps reverse it, by restoring lost nerve cell connections in the brain. “Current drugs on the market for Alzheimer’s patients offer…

An antibody therapy that ProMIS Neurosciences is developing for Alzheimer’s formed a bond with only the harmful forms of amyloid beta clusters associated with the disease, an indication that it could be an effective treatment, according to a preclinical-trial study. A good sign was that PMN310 didn’t bind to the forms…

A person’s awareness of a cognitive problem, such as memory loss, may be a good indication that he or she is not going to develop Alzheimer’s disease. According to a study conducted by researchers at the Centre for Addiction and Mental Health (CAMH) in Toronto, Canada, people who are unaware…

The U.S. Food and Drug Administration (FDA) has placed CT1812 on fast track as a potential treatment of patients with Alzheimer’s disease (AD), the investigative therapy’s developer,  Cognition Therapeutics, has announced. CT1812 is a first-in-class, orally administered small molecule designed to inhibit the binding of amyloid beta oligomers to nerve…

Ionis Pharmaceuticals has started a Phase 1/2 clinical trial to evaluate the Alzheimer’s therapy IONIS-MAPTRx. IONIS-MAPTRx is aimed at reducing the production of tau protein, whose accumulation in the brain is a hallmark of the disease. The trial will evaluate the therapy in patients with mild forms of Alzheimer’s. Therapies targeting…